2. Search Result
Search Result
Results for "

anti-HER2

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

2

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9907A
    Trastuzumab (anti-HER2)
    Maximum Cited Publications
    21 Publications Verification

    anti-Human HER2, Humanized antibody (PBS)

    		 ADC Antibody EGFR Cancer
    Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
    Trastuzumab (<em>anti-HER2</em>)
  • HY-P99030
    Margetuximab

    		EGFR Cancer
    Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .
    Margetuximab
  • HY-145674
    HDP 30.1699

    		Others Cancer
    HDP 30.1699, the derivative of α-Amanitin, shows considerable cross-links. The cysteine residues of the anti-HER2 THIOMAB antibody are used for conjugation of the cysteine reactive linker–Amanitin compound, HDP 30.1699, with a cleavable linker by maleimide chemistry [2].
    HDP 30.1699
  • HY-138298A
    Trastuzumab deruxtecan
    1 Publications Verification

    DS-8201; DS-8201a

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer [2].
    Trastuzumab deruxtecan
  • HY-110354
    UCM05

    G28UCM

    		 Fatty Acid Synthase (FASN) Bacterial Antibiotic Infection Cancer
    UCM05 (G28UCM) is a potent inhibitor of fatty acid synthase (FASN) shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines. UCM05 is a Filamentous temperature-sensitive protein Z (FtsZ) inhibitor and inhibits the growth of the Gram-positive bacterium B. subtilis with MIC values of 100 μM but lack activity on the Gram-negative bacterium E. coli.
    UCM05
  • HY-138298
    Trastuzumab deruxtecan (solution)
    1 Publications Verification

    DS-8201 (solution); DS-8201a (solution)

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer [2].
    Trastuzumab deruxtecan (solution)
  • HY-P9985
    Disitamab vedotin
    1 Publications Verification

    RC48

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity .
    Disitamab vedotin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: